Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rinatabart sesutecan + carboplatin
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Rinatabart sesutecan + carboplatin** is a combination therapy under investigation primarily for the treatment of advanced ovarian and endometrial cancers. Rinatabart sesutecan (Rina-S, PRO1184, GEN1184) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα), conjugated to a topoisomerase I inhibitor payload. The ADC is designed to bind FRα-expressing cancer cells, deliver the cytotoxic payload, and induce cancer cell death. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and subsequent apoptosis in rapidly dividing cells. This combination aims to achieve additive or synergistic anti-tumor activity, and is currently studied in platinum-sensitive and resistant gynecologic cancers.
- Other names
- rinatabart sesutecanRina-SPRO1184PRO-1184PRO 1184GEN1184GEN-1184GEN 1184
02
Targets
FOLR1 (FRα)TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on rinatabart sesutecan + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rinatabart sesutecan + carboplatin.